Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

Annie Mayence; Jean Jacques Vanden Eynde

doi:10.3390/ph12010037

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

Pharmaceuticals (Basel). 2019 Mar 12;12(1):37. doi: 10.3390/ph12010037.

Authors

Annie Mayence¹, Jean Jacques Vanden Eynde²

Affiliations

¹ Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium. annie.mayence@alumini.umons.ac.be.
² Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium. jean-jacques.vandeneynde@ex.umons.ac.be.

Abstract

In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.

Keywords: FDA; Janus kinases; approved drugs; baricitinib; protein kinase inhibitor; rheumatoid arthritis.